Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.22.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 12,725 $ 8,021
General and administrative 3,254 2,765
Total operating expenses 15,979 10,786
Loss from operations (15,979) (10,786)
Other (expense) income:    
Interest income 34 24
Change in fair value of warrant liabilities (4,212) 5,567
Total other (expense) income (4,178) 5,591
Net loss $ (20,157) $ (5,195)
Per share information:    
Net loss per share of common stock, basic and diluted $ (0.51) $ (0.18)
Basic and diluted weighted average shares outstanding 39,332,721 28,963,594